Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection
- Author(s)
- Teh, BW; Harrison, SJ; Pellegrini, M; Thursky, KA; Worth, LJ; Slavin, MA;
- Details
- Publication Year 2014-03,Volume 28,Issue #2,Page 75-86
- Journal Title
- Blood Reviews
- Publication Type
- Journal Article
- Abstract
- Plasma cell myeloma (PCM) is increasing in prevalence in older age groups and infective complications are a leading cause of mortality. Patients with PCM are at increased risk of severe infections, having deficits in many arms of the immune system due to disease and treatment-related factors. Treatment of PCM has evolved over time with significant impacts on immune function resulting in changing rates and pattern of infection. Recently, there has been a paradigm shift in the treatment of PCM with the use of immunomodulatory drugs and proteasome inhibitors becoming the standard of care. These drugs have wide-ranging effects on the immune system but their impact on infection risk and aetiology remain unclear. The aims of this review are to discuss the impact of patient, disease and treatment factors on immune function over time for patients with PCM and to correlate immune deficits with the incidence and aetiology of infections seen clinically in these patients. Preventative measures and the need for clinically relevant tools to enable infective profiling of patients with PCM are discussed. (C) 2014 Elsevier Ltd. All rights reserved.
- Publisher
- Elsevier
- Keywords
- Immune deficit; Infection; Myeloma; Treatment
- Research Division(s)
- Infection And Immunity
- Publisher's Version
- https://doi.org/10.1016/j.blre.2014.01.004
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2014-07-29 03:01:14